|
Clinical bottom line
There is no evidence that aspirin use in the first three months of pregnancy
results in any increased risk of congenital abnormalities.
Reference
E Kozer et al. Aspirin consumption during the first trimester of pregnancy and
congenital abnormalities: a meta-analysis. American Journal of Obstetrics and
Gynecology 2002 187: 1623-1630.
Meta-analysis
A very considerable search was undertaken for studies of any architecture that
examined the use of aspirin in pregnancy and congenital abnormalities. Five
electronic databases were searched, and texts and bibliographies were also examined
for studies.
Results
Twenty-two studies were identified, one randomised study and the others case
control or cohort studies. The main results are shown in the Table. There was no
association between aspirin use and overall abnormalities, but there was a small
increased risk for gastrochisis in a small number of women.
Table 1: Results of meta-analysis
|
Outcome
|
Studies
|
Exposed (n/N)
|
Control (n/N)
|
Odds ratio (95%CI)
|
| Congenital malformations |
8
|
888/16138
|
1935/49890
|
1.3 (0.9 to 1.9)
|
| Cardiac malformations |
6
|
692/15130
|
1772/48146
|
1.0 (0.9 to 1.1)
|
| Gastroschisis |
5
|
52/261
|
523/2449
|
2.4 (1.4 to 3.9)
|
Comment
Overall there was no evidence of any association between maternal aspirin
ingestion in the first trimester and congenital abnormality in the infant.
Gastroschisis (imperfect closure of the abdomen) may be associated with an increased
risk, but the numbers were small and much larger (at least 20 times) number would
need to be studied to be certain of this. This abnormality affects perhaps 3-6 per
100,000 births. The studies did not have confirmed diagnosis, and maternal disease
may have contributed to the result observed.
|